Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?
PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).
PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).
What's Your Reaction?
